Xvivo Perfusion AB (publ) (XVIPF)
OTCMKTS · Delayed Price · Currency is USD
19.00
0.00 (0.00%)
Sep 16, 2025, 8:00 PM EDT
Xvivo Perfusion AB Market Cap
Xvivo Perfusion AB has a market cap or net worth of $598.50 million as of September 18, 2025. Its market cap has decreased by -63.42% in one year.
Market Cap
598.50M
Enterprise Value
575.61M
Revenue
86.54M
Ranking
n/a
PE Ratio
51.10
Stock Price
$19.00
Market Cap Chart
Since October 8, 2012, Xvivo Perfusion AB's market cap has increased from 56.07M to 598.50M, an increase of 967.40%. That is a compound annual growth rate of 20.06%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Sep 17, 2025 | 598.50M | -57.08% |
| Dec 30, 2024 | 1.39B | 35.52% |
| Dec 29, 2023 | 1.03B | 96.50% |
| Dec 30, 2022 | 523.72M | -42.34% |
| Dec 30, 2021 | 908.22M | -17.47% |
| Dec 30, 2020 | 1.10B | 126.83% |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2015 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Nika Pharmaceuticals | 982.68M |
| Veradigm | 806.69M |
| Tian'an Technology Group | 792.01M |
| Elite Pharmaceuticals | 718.26M |
| Glass House Brands | 574.70M |
| CytoDyn | 377.06M |
| Northwest Biotherapeutics | 373.88M |
| American Oncology Network | 345.48M |